Physician profile
Danielle M Bailey
NPI 1902568736
$2,068.49
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.33 · 2022: $1,170 · 2023: $869 · 2024: $13.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $913.08 | 2022-2024 | |
| Glaxosmithkline, LLC. | $198.71 | 2022-2023 | Nucala, Trelegy Ellipta |
| Medical Device Business Services, INC. | $168.48 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.60 | 2022 | |
| Lilly USA, LLC | $71.96 | 2022-2023 | Mounjaro |
| Amgen INC. | $66.16 | 2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $61.01 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Mylan Specialty L.P. | $59.41 | 2022-2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $58.64 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $39.72 | 2022-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.59 | 2022-2023 | Stiolto Respimat, Spiriva Respimat |
| Astellas Pharma US INC | $31.67 | 2023 | Myrbetriq |
| Sanofi-Aventis U.S. LLC | $29.07 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $28.01 | 2022 | |
| Axsome Therapeutics, INC. | $26.55 | 2023 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $20.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.97 | 2023 | |
| Shield Therapeutics INC | $19.06 | 2023 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $18.28 | 2022 | |
| Novo Nordisk INC | $16.09 | 2023 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.73 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.05 | 2022 | |
| Pfizer INC. | $14.37 | 2023 | |
| Amarin Pharma, INC. | $14.31 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.01 | 2022 | |
| Sumitomo Pharma America, INC. | $11.32 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.